SAEs Meta-Analysis results.xlsâ , Table S4 SAEs Meta-Analysis results. (XLS 76 kb)

Reporting of AEs.xlsâ , Table S2 Reporting of adverse events in Clinical Study Reports (CSRs) and journal articles for Olistat trials. (XLS 31 kb)

Additional file 9: Table S5. Set of 2,426 target-adverse effects associations extracted from the target-ADE model.

Background The relationship between ERCC2 polymorphisms and the risk of radiotoxicity remains inconclusive. The aim of our study is to systematically evaluate the association...

Background Drug-target identification is crucial to discover novel applications for existing drugs and provide more insights about mechanisms of biological actions, such as...

Background The quality of harms reporting in journal publications is often poor, which can impede the risk-benefit interpretation of a clinical trial. Clinical study reports can...

Reporting of SAEs.xlsâ , Table S3 Reporting of serious adverse events (SAEs) in Clinical study reports (CSRs) and journal articles for Olistat trials. (XLS 65 kb)